In HER2-positive (HER2+) advanced BC (ABC), the recommended first-line treatment is the combination of HER2-targeted therapy (trastuzumab + pertuzumab) with taxane chemotherapy (docetaxel or paclitaxel), regardless of ER status [7]. This evidence concerns the gene ESR1 and breast cancer.